Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB

Nature Biotechnology

Volumn 20, Issue 2, 2002, Pages 143-148

  Maus, Marcela V ^a   Thomas, Anna K ^a   Leonard, Debra G B ^b   Allman, David ^a,b   Addya, Kathakali ^b   Schlienger, Katia ^a   Riley, James L ^a,b   June, Carl H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CELLS; IMMUNOLOGY; MOLECULAR BIOLOGY; TUMORS;

SURFACE MOLECULES;

BIOTECHNOLOGY;

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; POLYCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD28; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SEPARATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LIGANDS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 0036171757     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0202-143     Document Type: Article

References (43)

1. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes
2. Principles for adoptive T cell therapy of human viral diseases
3. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
4. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo
5. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
6. + HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant
7. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells
8. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
9. + T cells in the absence of exogenous feeder cells
10. + T cells become nonresponsive (anergic) following activation in the presence of costimulation
11. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: Implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging
12. + T cells
13. Inducible T cell antigen 4- 1BB. Analysis of expression and function
14. Molecular cloning of a ligand for the inducible T cell gene 41BB: A member of an emerging family of cytokines with homology to tumor necrosis factor
15. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death
16. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28
17. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4- 1BB ligand
18. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
19. Cutting edge: 4- 1BB is a bona fide CD8 T cell survival signal
20. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination
21. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
22. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway
23. Costimulation of CD28T lymphocytes by 4-1BB ligand
24. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine
25. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells
26. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'
27. Clinical significance of defective dendritic cell differentiation in cancer
28. Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
29. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
30. In vivo tracking of tumor-specific T cells
31. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
32. The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc
33. Expression of bcl-X(L) restores cell survival, but not proliferation of effector differentiation, in CD28-deficient T lymphocytes
34. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
35. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
36. +) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD 8 signaling in response to antigen
37. Activation and differentiation requirements of primary T cells in vitro
38. +T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells
39. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer
40. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis
41. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression
42. ICOS costimulation requires IL-2 and can be prevented by CTLA4 engagement
43. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion